Ulcerative Colitis - Pipeline Review, H2 2015 Now Available at iData Insights Ulcerative Colitis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ulcerative Colitis Pipeline Review, H2 2015, provides an overview of the Ulcerative Colitis s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the 1
therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179089/ulcerative-colitis-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179089/ulcerative-colitis-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Ulcerative Colitis Overview 12 Therapeutics Development 13 Pipeline Products for Ulcerative Colitis - Overview 13 Pipeline Products for Ulcerative Colitis - Comparative Analysis 14 Ulcerative Colitis - Therapeutics under Development by Companies 15 Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 22 Ulcerative Colitis - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Ulcerative Colitis - Products under Development by Companies 27 Ulcerative Colitis - Products under Investigation by Universities/Institutes 32 Ulcerative Colitis - Companies Involved in Therapeutics Development 33 2
4D Pharma Plc 33 Advinus Therapeutics Ltd. 34 Ajinomoto Pharmaceuticals Co., Ltd. 35 Altheus Therapeutics, Inc. 36 Am-Pharma B.V. 37 Amgen Inc. 38 Arena Pharmaceuticals, Inc. 39 Astellas Pharma Inc. 40 Atlantic Healthcare Plc 41 Avaxia Biologics, Inc. 42 BioAtla, LLC 43 BioLineRx, Ltd. 44 Bionovis SA 45 Celgene Corporation 46 Cellceutix Corporation 47 Celltrion, Inc. 48 ChemoCentryx, Inc. 49 ChironWells GmbH 50 Chong Kun Dang Pharmaceutical Corp. 51 Cosmo Pharmaceuticals S.p.A 52 Dr. Falk Pharma GmbH 53 Effimune SAS 54 Eli Lilly and Company 55 3
Emergent BioSolutions Inc. 56 Enceladus Pharmaceuticals BV 57 enGene, Inc 58 Enterome Bioscience SA 59 Epirus Biopharmaceuticals, Inc. 60 Flexion Therapeutics, Inc. 61 Galapagos NV 62 Genentech, Inc. 63 Genor BioPharma Co., Ltd. 64 Gilead Sciences, Inc. 65 GW Pharmaceuticals Plc 66 Hetero Drugs Limited 67 iCo Therapeutics Inc. 68 Idera Pharmaceuticals, Inc. 69 InDex Pharmaceuticals AB 70 Innovate Biopharmaceuticals, Inc. 71 INOXIA Lifesciences GmbH 72 Intas Pharmaceuticals Ltd. 73 Invion Limited 74 Johnson & Johnson 75 Kaken Pharmaceutical Co., Ltd. 76 Kymab Limited 77 LIPID THERAPEUTICS GmbH 78 LTT Bio-Pharma Co., Ltd. 79 4
Mabion SA 80 Mabtech Limited 81 Medestea Research & Production S.p.A. 82 Momenta Pharmaceuticals, Inc. 83 Morphotek, Inc. 84 Mycenax Biotech Inc. 85 Oncobiologics, Inc. 86 Pfizer Inc. 87 Pluristem Therapeutics Inc. 88 ProtAb Ltd 89 Protagonist Therapeutics Inc. 90 Qu Biologics Inc. 91 Rebiotix Inc. 92 Receptos, Inc. 93 Sandoz International GmbH 94 Seres Therapeutics, Inc. 95 Sigmoid Pharma Limited 96 Stelic Institute & Co. 97 sterna biologicals Gmbh & Co KG 98 Synergy Pharmaceuticals, Inc. 99 Takeda Pharmaceutical Company Limited 100 Therapeutic Proteins International, LLC 101 Therapix Biosciences Ltd 102 5
Theravance Biopharma, Inc. 103 Tillotts Pharma AG 104 Trino Therapeutics Limited 105 Ventria Bioscience 106 Zyngenia, Inc. 107 Ulcerative Colitis - Therapeutics Assessment 108 Assessment by Monotherapy Products 108 Assessment by Combination Products 109 Assessment by Target 110 Assessment by Mechanism of Action 115 Assessment by Route of Administration 119 Assessment by Molecule Type 121 Drug Profiles 123 (mesalamine + N-acetylcysteine) - Drug Profile 123 abrilumab - Drug Profile 125 ABS-11 - Drug Profile 126 adalimumab biosimilar - Drug Profile 127 adalimumab biosimilar - Drug Profile 128 adalimumab biosimilar - Drug Profile 129 adalimumab biosimilar - Drug Profile 130 adalimumab biosimilar - Drug Profile 131 adalimumab biosimilar - Drug Profile 132 adalimumab biosimilar - Drug Profile 133 adalimumab biosimilar - Drug Profile 134 6
adalimumab biosimilar - Drug Profile 135 adalimumab biosimilar - Drug Profile 136 adalimumab biosimilar - Drug Profile 137 adalimumab biosimilar - Drug Profile 138 adalimumab biosimilar - Drug Profile 139 AJM-300 - Drug Profile 140 AKP-11 - Drug Profile 142 alicaforsen sodium - Drug Profile 144 Anatabine - Drug Profile 145 Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer - Drug Profile 147 APD-334 - Drug Profile 148 apremilast - Drug Profile 149 ASP-3291 - Drug Profile 152 AVX-470 - Drug Profile 153 AW/EPO-002 - Drug Profile 155 AW/EPO-003 - Drug Profile 156 AW/EPOPD-01 - Drug Profile 157 AW/EPOPD-02 - Drug Profile 158 AW/EPOPD-06 - Drug Profile 159 bertilimumab - Drug Profile 160 BL-7040 - Drug Profile 162 brilacidin tetrahydrochloride - Drug Profile 164 budesonide - Drug Profile 166 7
CCX-507 - Drug Profile 169 CKD-506 - Drug Profile 170 cyclosporine CR - Drug Profile 171 D-9030 - Drug Profile 172 DIMS-0150 - Drug Profile 173 dolcanatide - Drug Profile 176 Drug to Inhibit Phospholipase A2 for Crohn's Disease and Ulcerative Colitis - Drug Profile 177 Drugs for Ulcerative Colitis - Drug Profile 178 EB-120 - Drug Profile 179 EFFI-7H - Drug Profile 180 EG-10 - Drug Profile 181 EG-12 - Drug Profile 182 enalaprilat - Drug Profile 183 ES-210 - Drug Profile 184 Read More http://www.idatainsights.com/reports-landing-page.php?id=179089/ulcerative-colitispipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights 8
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
9